X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RJVA-001 is the Company’s first GLP-1 gene therapy candidate to emerge from the Rejuva platform, setting the stage for a potentially transformative approach to treating metabolic diseases, including obesity and T2D.
Lead Product(s): RJVA-001
Therapeutic Area: Nutrition and Weight Loss Product Name: RJVA-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
RJVA-001 is the first GLP-1 pancreatic gene therapy (GLP1 PGTx) candidate, which is being evaluated in preclinical studies for the treatment of Type 2 Diabetes (T2D).
Lead Product(s): AAV-Delivered Pancreatic Gene Therapy
Therapeutic Area: Endocrinology Product Name: RJVA-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Details:
The net proceeds will be used to fund the continued preclinical development of our Rejuva, a GLP-1-based pancreatic gene therapy candidate, for treatment across the spectrum of type 2 diabetes and obesity.
Lead Product(s): AAV-based Pancreatic Gene Therapy
Therapeutic Area: Endocrinology Product Name: Rejuva
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 15, 2023
Details:
The collaboration aims to explore mechanisms of metabolic improvement and weight loss from an intrapancreatic gene therapy leveraging GLP-1-based transgenes for long-duration treatment of type 2 diabetes (T2D) and obesity.
Lead Product(s): Pancreatic Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Michigan Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 16, 2023
Details:
Fractyl Health is developing not only an AAV vector platform, but also local delivery devices and methods to potentially enable Pancreatic GLP-1 Gene Therapy.
Lead Product(s): Pancreatic GLP-1 Gene Therapy
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
